Park Place Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Park Place Capital’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$674	Hold	18	–	–	﹤0.01%	1075
2026 Q1	$654	Hold	18	–	–	﹤0.01%	830
2025 Q4	$838	Hold	18	–	–	﹤0.01%	769
2025 Q3	$750	Hold	18	–	–	﹤0.01%	768
2025 Q2	$512	Hold	18	–	–	﹤0.01%	795
2025 Q1	$604	Hold	18	–	–	﹤0.01%	804
2024 Q4	$920	Hold	18	–	–	﹤0.01%	788
2024 Q3	$920	Hold	18	–	–	﹤0.01%	827
2024 Q2	$806	Hold	18	–	–	﹤0.01%	840
2024 Q1	$843	Buy	+18	New	+$704	﹤0.01%	887

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Park Place Capital's CRNX Position: Q2 2026 in Review

Park Place Capital held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 18 shares worth $674. The position accounts for ﹤0.01% of the portfolio, ranked #1075.

Park Place Capital first reported a position in CRNX in Q1 2024 and has held it in 10 quarters since. The position peaked at $920 in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Park Place Capital held 18 shares of Crinetics Pharmaceuticals worth $674 as of Q2 2026.
Park Place Capital left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of Park Place Capital's portfolio in Q2 2026, its #1075 holding.
Park Place Capital first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Park Place Capital's Crinetics Pharmaceuticals position peaked at $920 in Q4 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.